The University of Chicago Header Logo

Connection

Kathleen Mullane to Anti-Bacterial Agents

This is a "connection" page, showing publications Kathleen Mullane has written about Anti-Bacterial Agents.
Connection Strength

2.830
  1. Management of Clostridioides (formerly Clostridium) difficile infection (CDI) in solid organ transplant recipients: Guidelines from the American Society of Transplantation Community of Practice. Clin Transplant. 2019 09; 33(9):e13564.
    View in: PubMed
    Score: 0.448
  2. A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation. Clin Infect Dis. 2019 01 07; 68(2):196-203.
    View in: PubMed
    Score: 0.435
  3. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial. J Antimicrob Chemother. 2016 10; 71(10):2964-71.
    View in: PubMed
    Score: 0.366
  4. Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1435-40.
    View in: PubMed
    Score: 0.328
  5. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013; 38(1):1-11.
    View in: PubMed
    Score: 0.296
  6. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011 Sep; 53(5):440-7.
    View in: PubMed
    Score: 0.261
  7. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev Anti Infect Ther. 2011 Jul; 9(7):767-77.
    View in: PubMed
    Score: 0.258
  8. Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections. Antimicrob Agents Chemother. 2015 Mar; 59(3):1441-5.
    View in: PubMed
    Score: 0.082
  9. Reply to M.R. Green et al. J Clin Oncol. 2013 Dec 01; 31(34):4379.
    View in: PubMed
    Score: 0.076
  10. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol. 2013 Jul 01; 31(19):2493-9.
    View in: PubMed
    Score: 0.074
  11. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis. 2013 Mar 25; 13:148.
    View in: PubMed
    Score: 0.073
  12. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011 Feb 03; 364(5):422-31.
    View in: PubMed
    Score: 0.063
  13. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother. 2009 Jan; 53(1):223-8.
    View in: PubMed
    Score: 0.054
  14. Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis. 2012 Aug; 55 Suppl 2:S121-6.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.